Physician profile
Jaime C Lim
NPI 1013979285
$2,781.33
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $1,385 · 2021: $365 · 2022: $161 · 2023: $40.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $704.40 | 2019-2021 | |
| Emd Serono, INC. | $268.91 | 2020 | |
| Novartis Pharmaceuticals Corporation | $257.41 | 2019-2022 | |
| Abbvie INC. | $193.43 | 2021-2023 | |
| Allergan, INC. | $188.72 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $140.14 | 2019-2020 | |
| Acorda Therapeutics, INC | $121.62 | 2019 | |
| Amgen INC. | $120.02 | 2019-2022 | |
| Genzyme Corporation | $115.68 | 2019-2020 | |
| Biogen, INC. | $114.15 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $91.38 | 2019-2020 | |
| Lilly USA, LLC | $58.14 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $57.44 | 2019-2020 | |
| Sk Life Science, INC. | $44.58 | 2020 | |
| Upsher-Smith Laboratories LLC | $31.72 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $31.38 | 2020 | |
| Tanabe Pharma America, INC. | $29.50 | 2020-2021 | |
| Kyowa Kirin, INC. | $28.22 | 2020 | |
| Lundbeck LLC | $28.06 | 2020 | |
| Ucb, INC. | $24.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.50 | 2019 | |
| Si-Bone, INC. | $15.59 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $15.40 | 2020 | |
| Pfizer INC. | $14.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.17 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.09 | 2021 | |
| Grifols USA, LLC | $12.97 | 2019 | |
| Currax Pharmaceuticals LLC | $12.82 | 2020 | |
| Horizon Therapeutics Plc | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.